Viruses in head and neck cancers: Prevention and therapy

Expert Review of Anticancer Therapy

Volumn 8, Issue 9, 2008, Pages 1365-1371

  Psyrri, Amanda ^a,b   Burtness, Barbara ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

CANCER IMMUNOTHERAPY; CANCER RISK; CELL TRANSPLANTATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; EDITORIAL; EPSTEIN BARR VIRUS; HEAD AND NECK CANCER; HUMAN; NASOPHARYNX CANCER; NONHUMAN; OROPHARYNX CANCER; PROGNOSIS; RISK FACTOR; RISK REDUCTION; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; EPSTEIN-BARR VIRUS INFECTIONS; HEAD AND NECK NEOPLASMS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY; NASOPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 55249125734     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.9.1365     Document Type: Editorial

References (66)

1. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl Cancer Inst. 92(9), 709-720 (2000).
2. Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J. Clin. Oncol. 24(5), 736-747 (2006).
3. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 103(9), 1843-1849 (2005).
4. Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ. Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 11(6), 489-495 (2000).
5. Canto MT, Devesa SS. Oral cavity and pharynx cancer incidence rates in the United States, 1975-1998. Oral Oncol. 38(6), 610-617 (2002).
6. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J. Clin. Oncol. 26(4), 612-619 (2008).
7. Fleming DT, Mcquillan GM, Johnson RE et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337(16), 1105-1111 (1997).
8. Adelstein DJ, Li Y, Adams GL et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 21(1), 92-98 (2003).
9. Licitra L, Perrone F, Bossi P et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 24(36), 5630-5636 (2006).
10. Mellin H, Dahlgren L, Munck-Wikland E et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int. J. Cancer 102(2), 152-158 (2002).
11. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 79(3), 595-604 (1997).
12. Li W, Thompson CH, O'Brien CJ et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int. J. Cancer 106(4), 553-558 (2003).
13. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol. Head Neck Surg. 125(1), 1-9 (2001).
14. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl Cancer Inst. 100(4), 261-269 (2008).
15. Munger K, Baldwin A, Edwards KM et al. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78(21), 11451-11460 (2004).
16. Goodwin EC, Dimaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc. Natl Acad. Sci. USA 97(23), 12513-12518 (2000).
17. Tan TM, Ting RC. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res. 55(20), 4599-4605 (1995).
18. Wheeler CM. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat. Clin. Pract. Oncol. 4(4), 224-235 (2007).
19. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447), 1757-1765 (2004).
20. Koutsky LA, Harper DM. Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine 24(Suppl. 3), S114-S121 (2006).
21. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. 6(5), 271-278 (2005).
22. Maeda H, Kubo K, Sugita Y et al. DNA vaccine against hamster oral papillomavirus-associated oral cancer. J. Int. Med. Res. 33(6), 647-653 (2005).
23. McNeil C. Human papillomavirus and oral cancer: looking toward the clinic. J Natl Cancer Inst. 100(12), 840-842 (2008).
24. Halpert R, Fruchter RG, Sedlis A et al. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet. Gynecol. 68(2), 251-258 (1986).
25. Schafer A, Friedmann W, Mielke M, Schwartlander B, Koch MA. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am. J. Obstet. Gynecol. 164(2), 593-599 (1991).
26. Laga M, Icenogle JP, Marsella R et al. Genital papillomavirus infection and cervical dysplasia - opportunistic complications of HIV infection. Int. J. Cancer 50(1), 45-48 (1992).
27. Brandsma JL. Animal models of human- papillomavirus-associated oncogenesis. Intervirology 37(3-4), 189-200 (1994).
28. Tagami H. Regression phenomenon of numerous flat warts - an experiment on the nature of tumor immunity in man. Int. J. Dermatol. 22(10), 570-571 (1983).
29. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 181(1), 62-69 (1991).
30. Devaraj K, Gillison ML, Wu TC. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit. Rev. Oral Biol. Med. 14(5), 345-362 (2003).
31. Chen L, Ashe S, Brady WA et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71(7), 1093-1102 (1992).
32. Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23(9), 2242-2249 (1993).
33. Lin KY, Guarnieri FG, Staveley-O'Carroll KF et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56(1), 21-26 (1996).
34. Greenstone HL, Nieland JD, De Visser KE et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl Acad. Sci. USA 95(4), 1800-1805 (1998).
35. Chu NR, Wu HB, Wu T et al. Immunotherapy of a human papillomavirus (HPV) type 16 E7 - expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. 121(2), 216-225 (2000).
36. Daemen T, Pries F, Bungener L et al. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther. 7(21), 1859-1866 (2000).
37. Brandsma JL, Shlyankevich M, Zelterman D, Su Y. Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. Vaccine 25 (33), 6158-6163 (2007).
38. Liu DW, Tsao YP, Hsieh CH et al. Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J. Virol. 74 (19), 9083-9089 (2000).
39. Liu DW, Yang YC, Lin HF et al. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201 -restricted T-cell peptides in cervical cancer patients. J. Virol. 81(6), 2869-2879 (2007).
40. Gerard CM, Baudson N, Kraemer K et al. Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic: mice. Clin. Cancer Res. 7(3 Suppi.), 838s-847s (2001).
41. Gunn GR, Zubair A, Peters C et al. Two Listeria monocytagenes vaccine vectors that express different molecular forms of human papilloma virus- 16 (HPV- 16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 167(11), 6471-6479 (2001),
42. Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281(2), 231-238 (2001).
43. Zehbe I, Wilander E, Delius H, Tommasino, M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 58(4), 829-833 (1998).
44. Pinto LA, Edwards J, Castle PE et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. 188(2), 327-338 (2003).
45. Borysiewicz LK, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347(9014), 1523-1527 (1996).
46. Hsu KF, Hung CF, Cheng WF et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Tber. 8(5), 376-383 (2001).
47. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol. 13(7), 1007-1015 (2002).
48. Lacy J, Loomis R, Grin S et al. Systemic Bd-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice. Int J Cancer 119(2), 309-316 (2006).
49. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM. The Epstein-Baff virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor k B. J Biol. Chem. 267(34), 24157-24160 (1992).
50. Kenney JL, Guinness ME, Curiel T, Lacy J. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Bload 99(5), 1721-1727 (1998).
51. Chua D, Huang J, Zheng B et al. Adoptive transfer of autologous Epstem-Barr virus-specific cytotomc T cells for nasopharyngeal carrinoma. Int. J. Cancer 94(1), 73-80 (2001).
52. Khanna R, Busson P, Burrows SR et al. Molecular characterization of antigen processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC oells. Cancer Res. 58(2), 310-314 (1998).
53. Meij P, Leen A, Rickinson AB et al. Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus encoded latent membrane protein 1 and latent membrane protein 2. Int. J. Cancer 99(1), 93-99 (2002).
54. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15, 405-431 (1997).
55. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy, for posttransplant lymphoproliferative disease. Br. J. Haematol. 118(3), 728-740 (2002).
56. Whitney BM, Chan AT, Rickinscin AB et al. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocyte, in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. J. Med. Virol. 67(3), 359-363 (2002).
57. Comoli P, De Palma R, Siena S et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann. Oncol. 15(1), 113-117 (2004).
58. Straathof KC, Bollard CM, Popat U et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105 (5), 1898-1904 (2005).
59. Comoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23(35), 8942-8949 (2005).
60. Thorley-Lawson DA, Poodry CA. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol. 43(2), 730-736 (1982).
61. North JR, Morgan AJ, Thompson JL, Epstein MA. Quantification of an Epstein-Barr virus-associated membrane antigen component. J Virol. Methods 5(1), 55-65 (1982).
62. North JR, Morgan AJ, Thompson JL, Epstein MA. Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes. Proc. Natl. Acad. Sci. USA 79(23), 7504-7508 (1982).
63. Epstein MA, Morgan AJ, Finerty S, Randle BJ, Kirkwood JK. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 318(6043), 287-289 (1985).
64. Mei YP, Zhu XF, Zhou JM et al. siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression. Cancer Lett. 232(2), 189-198 (2006).
65. Chen S, Gao G, Chen W et al. VEGF-specific siRNAs modified with 2′-deoxy effectively suppress VEGF expression and inhibit growth of nasopharyngeal carcinoma xenograft in a mouse model. Sci. China C. Life Sci. 51(2), 104-110 (2008).
66. Wang Y, Duan HG, Chen SM et al. Effect of RNA interference targeting human telomerase revede transcriptase on telomerase and its related protein expression in nasopharyngeal carcinoma cells. J. Laryngol. Otol. 121(5), 476-482 (2007).